Skip to main content
Anita D’Souza on Muck Rack

Anita D’Souza

As seen in: Nature, Science Magazine, Cell Press, Dove Medical Press, OncLive, American Affairs, BioCentury
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anita

Contact Anita, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma

|
By Chongxu Shi, Matthieu Galtier, Adam S. Sperling, Benjamin A. Derman, Sarah Nikiforow, Alejandro Alonso Verified, Shuntaro Ikegawa, Nina Orwitz, David Quinn, David Pearson, Dexiu Bu, Pedro Milanez-Almeida, Omar Nadeem, Anita D’Souza, Allison Charles, Jerome Ritz, Andrzej J. Jakubowiak, Serena De Vita, Nikhil C. Munshi, Jennifer Mataraza, Jessica Liegel, Marc Credi
| Science Magazine Verified
Editor’s summary Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Editor’s summary A major challenge with traditional chimeric antigen receptor (CAR) T cell manufacturing is the time it takes to go from apheresis to product infusion, which creates the risk for a patient’s disease to progress in the meantime. Here, Sperling et al.
Open in Who Shared Issue with article?

Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis - Leukemia

|
By Meera Mohan, Charlotte Wagner, Carolina Schinke, Binod Dhakal, Anita D’Souza, Aniko Szabo
| Nature Verified
To the Editor: Extramedullary disease (EMD) is a risk factor for poor outcomes in multiple myeloma (MM) [1,2,3], including amongst recipients of chimeric antigen receptor T-cell therapy (CAR-T) [4, 5]. With CD-19 CAR-T, discordant responses have also been observed, with clearance of disease in the marrow and persistence of disease in extramedullary sites, highlighting how CAR-T activity may be limited in extramedullary sites [6].
Open in Who Shared Issue with article?

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma | Blood Cancer Journal

|
By Meera Mohan, Aniko Szabo, Binod Dhakal, Samer A. Al-Hadidi, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty
| Nature Verified
Abstract The main objective of this multi-institutional study is to understand the effect of primary intravenous immunoglobulin (IVIG) replacement on clinical outcomes in recipients of BCMA-directed bispecific antibody (bsAb), where infection remains an important cause of morbidity and mortality. This is a retrospective study of patients treated with either standard of care teclistamab or BCMA-directed investigational bsAb between Nov 2017 and Dec 2023.
Open in Who Shared Issue with article?
See all 17 licensed articles (18 Total)